DataLookout › Non-Hodgkin Lymphoma Clinical Trials

Non-Hodgkin Lymphoma Clinical Trial Monitor — CAR-T, BTKi & Bispecific Pipeline Alerts 2026

13+ recruiting non-Hodgkin lymphoma trials on ClinicalTrials.gov — spanning DLBCL, follicular lymphoma, mantle cell, marginal zone, and T-cell subtypes. Daily alerts on bispecific antibodies, BTK degraders, CAR-T programs, and combination regimens delivered to your inbox.

Get Free NHL Trial Alerts

The NHL trial landscape in 2026

Non-Hodgkin lymphoma is not one disease — it is a family of more than 60 distinct malignancies arising from B cells, T cells, and NK cells at various stages of lymphoid differentiation. NHL is the most common hematologic malignancy in the United States, with approximately 80,000 new diagnoses annually. The landscape of NHL clinical trials has undergone a more rapid transformation over the past five years than almost any other oncology indication, driven by three convergent technology waves: CD19-targeted CAR-T cell therapies achieving durable remissions in patients who had exhausted all other options; bispecific antibodies delivering comparable efficacy with far simpler logistics; and next-generation BTK inhibitors and BTK degraders reshaping the frontline and relapsed/refractory treatment landscape for B-cell lymphomas and CLL.

The competitive intelligence challenge in NHL is its subtype complexity. A drug that works in DLBCL (diffuse large B-cell lymphoma, the most common NHL subtype) may not work in follicular lymphoma (FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) — each of which has distinct biology, different approved therapies, and a separate pipeline. T-cell lymphomas (peripheral T-cell lymphoma, PTCL; cutaneous T-cell lymphoma, CTCL) are biologically entirely distinct and require separate monitoring. Companies operating across multiple NHL subtypes face a monitoring challenge that generic ClinicalTrials.gov alerts handle poorly: the same keyword "lymphoma" catches hundreds of irrelevant studies, while subtype-specific keyword sets require careful configuration to avoid missed signals.

DataLookout currently tracks 13 recruiting NHL trials — representing the cross-section of the most important active programs — with the following major sponsors and studies active in 2026: AstraZeneca (AZD0486, a next-generation CD19xCD3 bispecific), NCI (nivolumab combination studies in relapsed NHL), BeOne Medicines (BGB-16673, a covalent BTK degrader in B-cell malignancies), and the NCI's ViPOR regimen trial (venetoclax + ibrutinib + prednisone + obinutuzumab + lenalidomide in relapsed aggressive NHL). Each of these represents a different strategic thesis about where the NHL competitive landscape is heading over the next three to five years.

Key mechanisms and active drug programs in 2026 NHL trials

Get daily NHL trial alerts by subtype

Set separate profiles for DLBCL, follicular lymphoma, mantle cell, and T-cell lymphomas — or track the full NHL landscape in one digest. Free plan available.

Start Free — No Credit Card

What DataLookout monitors for non-Hodgkin lymphoma

DataLookout checks ClinicalTrials.gov daily. For an NHL monitoring profile, you can configure:

Deep dive: Bispecific antibodies — outpacing CAR-T in follicular lymphoma?

The approval of mosunetuzumab (Lunsumio, Roche/Genentech) by the FDA in December 2022 for relapsed/refractory follicular lymphoma after two or more prior lines of therapy made it the first bispecific T-cell engager approved in any indolent B-cell lymphoma — and set off a competitive race that is directly relevant to anyone monitoring the NHL pipeline in 2026.

The clinical argument for bispecifics over CAR-T in follicular lymphoma is straightforward: FL is an incurable but typically slow-growing disease where patients may live for 15–20 years through multiple lines of therapy. CAR-T requires lymphodepletion chemotherapy, in-patient monitoring for CRS and ICANS, specialized apheresis infrastructure, and 4–6 weeks of manufacturing time. The toxicity profile and logistical burden are acceptable in DLBCL where the alternative is rapid progression and death — but in FL where the patient population is older, often in good health between relapses, and has a much longer natural history, the risk-benefit calculus shifts. Bispecifics can be administered in standard oncology infusion centers, dose-escalation can be managed outpatient, and the treatment course is finite (typically 8–17 cycles to deep response, then potentially stopped).

The pivotal data is compelling. Mosunetuzumab achieved an ORR of 80% and CR rate of 60% in heavily pretreated relapsed/refractory FL (CELESTIMO trial). Epcoritamab produced an ORR of 82% in a similar population. These response rates rival or exceed what CD19 CAR-T (axicabtagene and tisagenlecleucel) achieved in the pivotal trials that led to their approval in LBCL — but in FL, CAR-T is not yet approved and the Phase 2 data are still maturing.

The competitive intelligence question for 2026 is: who is running the pivotal Phase 3 bispecific vs. CAR-T comparison trial in FL, and what endpoints are being used? If bispecifics demonstrate non-inferior PFS with superior tolerability and accessibility, the approval landscape shifts dramatically — and companies running CAR-T manufacturing platforms for FL need to know this is coming. DataLookout's daily NHL alerts catch every new Phase 2/3 enrollment opening in follicular lymphoma as it registers on ClinicalTrials.gov, including the AstraZeneca AZD0486 Phase 2 expansion cohorts targeting FL specifically.

For hematology oncology BD teams, the bispecific-in-FL story also raises the question of earlier lines. Multiple Phase 2 studies are now investigating bispecifics in second-line FL, combined with obinutuzumab or lenalidomide in frontline FL, and in combination with PI3K inhibitors in double-refractory FL. The trial activity is dense enough that manual monitoring via ClinicalTrials.gov search is no longer practical — and the signals are moving fast enough that a week's lag in intelligence can affect the timing of a partnership offer or a go/no-go decision on a competing program.

Who uses NHL trial monitoring

Hematology oncology BD teams at pharma and biotech

Companies with CAR-T platforms, bispecific antibody programs, BTK inhibitors, or BCL-2 agents all need comprehensive NHL competitive intelligence because the competitive dynamics across subtypes are evolving rapidly and not always in predictable directions. The bispecific-vs-CAR-T dynamic in FL is one example; the BTK degrader threat to approved covalent BTKi franchises in MCL and CLL is another. BD teams at both large pharma (AstraZeneca, Roche, BMS, J&J) and mid-size biotech (BeOne, ADC Therapeutics, Nurix) use DataLookout to maintain daily awareness of who is registering new trials, in which NHL subtype, and at what phase — and to identify early-stage academic programs that might be worth a licensing conversation before they attract larger partners.

CAR-T program managers and cell therapy operations teams

Manufacturing-constrained CAR-T programs face competition from off-the-shelf bispecifics that can be deployed without the logistical infrastructure required for apheresis and individualized manufacturing. Program managers at companies with CAR-T platforms track the bispecific trial landscape specifically to monitor response rates, durability data, and the Phase 3 design decisions competitors are making — because these will define the evidence package that the bispecific programs bring to FDA and that will determine the commercial positioning relative to CAR-T.

Lymphoma patient advocacy organizations

Organizations including the Lymphoma Research Foundation, Leukemia & Lymphoma Society (LLS), and subtype-specific groups like the Follicular Lymphoma Foundation monitor the ClinicalTrials.gov pipeline for their patient communities — to identify trials appropriate for member referral, to inform advocacy positions on accelerated approval and real-world evidence requirements, and to track the progress of programs they help fund through their research grant infrastructure.

Hematology CROs and clinical operations teams

Contract research organizations conducting NHL trials need competitive intelligence to assess patient enrollment feasibility — specifically, whether competing trials for the same patient population are likely to be open simultaneously and drawing from the same referral networks. When multiple Phase 2 bispecific trials target the same relapsed/refractory FL population, enrollment competition becomes a serious operational risk. DataLookout's daily alerts let CRO protocol teams assess the competitive enrollment landscape in real time.

Start monitoring the NHL pipeline today

Free plan available — 1 subtype or keyword profile, weekly digest, no credit card required.

Get Free Alerts

How DataLookout works

DataLookout connects directly to the ClinicalTrials.gov API and checks for new and updated studies every morning. You specify condition keywords, intervention keywords, phase, sponsor type, and recruitment status. We filter, deduplicate, and deliver a clean digest to your inbox daily or weekly. No manual searching. No missed registrations. Reply to any digest email to update your search profile.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.